Extended indication Tildrakizumab monotherapy for treatment of active Psoriatic arthritis in adults and elderly who have no prior exposure to anti-tumor necrosis factor a
Therapeutic value No estimate possible yet
Registration phase Clinical trials

Product

Active substance Tildrakizumab
Domain Chronic immune diseases
Reason of inclusion New medicine (specialité)
Main indication Skin diseases
Extended indication Tildrakizumab monotherapy for treatment of active Psoriatic arthritis in adults and elderly who have no prior exposure to anti-tumor necrosis factor agent.
Proprietary name Ilumetri
Manufacturer Almirall
Portfolio holder Almirall
Mechanism of action Interleukin inhibitor
Route of administration Subcutaneous
Therapeutical formulation Injection
Budgetting framework Intermural (MSZ)

Registration

Registration route Centralised (EMA)
Type of trajectory Normal trajectory
Particularity Unknown
ATMP No
Submission date 2026
Expected Registration 2027
Orphan drug No
Registration phase Clinical trials
Additional remarks Fabrikant verwacht indiening in eerste kwartaal van 2026.

Therapeutic value

Therapeutic value No estimate possible yet

This assessment does not indicate any potential inclusion in the package.

References NCT04314531

Expected patient volume per year

Patient volume

Market share is generally not included unless otherwise stated.

Expected cost per patient per year

Cost 17,575.00 - 35,150.00

This amount gives an indication of the total cost. It is the result of the average expected patient volume times the average cost per patient. both per year.

References Medicijnkosten.nl
Additional remarks De prijs voor 100 mg Ilumetri is €3.192,82 (incl. BTW). Er zijn zes injecties van 100 mg nodig in het eerste jaar. Dit is €17.575,16 (excl. BTW). Er kan ook gekozen worden voor een dubbele dosis, dit kost dan €35.150,31 (excl. BTW).

Potential total cost per year

Off label use

Off label use Unknown

Indication extension

Indication extensions Unknown

Other information